Glulisine
Phase 3Small molecule
Glulisine is one of 37 small molecule programs targeting Coronary Artery Bypass. It is currently in Phase 3.
1
Indications
4
Total Trials
0
Active Trials
36
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
148 competitors in Coronary Artery Bypass
#DrugCompanyPhaseTrials
1Xe-133
NNobilis Therapeutics Inc.
Phase 3
Altoprev
CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Phase 3
Bactroban
PPadagis LLC
Phase 3
Arixtra
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Phase 3
Glargine Insulin
AstraZenecaPhase 3
Low-Dose Aspirin
PPharmaEssentia Japan K.K.
Phase 3
Iron Sulphate
PPierre Fabre Pharma GmbH
Phase 3
Pexelizumab
AstraZenecaPhase 3
Acadesine
Merck & Co.Phase 3
Polysaccharide Iron Complex
NNova Scotia Health Authority
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Efficacy and Safety1 trial
Comparison on Efficacy and Safety of Three Inpatient Insulin Therapy in Type2 DM
Completed·—·N/A·NCT01855243·63 enrolled
Hospitalized Patients1 trial
Comparison of Apidra to Regular Insulin in Hospitalized Patients
Completed·—·N/A·NCT00528918·300 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Glulisine. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 3[1]
- Company
- EEmory University